

# Tuberculosis profile: Democratic People's Republic of Korea

Population 2022: 26 million

## Estimates of TB burden\*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	134 000 (115 000-154 000)	513 (441-590)
HIV-positive TB incidence		
MDR/RR-TB incidence**	5 200 (1 500-9 000)	20 (5.6-35)
HIV-negative TB mortality		
HIV-positive TB mortality		

## Estimated proportion of TB cases with MDR/RR-TB\*, 2022

New cases	2.4% (0.98-5)
Previously treated cases	13% (2.8-34)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2022	61% (53-71)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	19% (13-26)

## TB case notifications, 2022

Total new and relapse	81 776
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	0%
- % pulmonary	79%
- % bacteriologically confirmed ^	46%
- % children aged 0-14 years	5%
- % women (aged ≥15 years)	35%
- % men (aged ≥15 years)	60%
Total cases notified	87 456

## TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	0	
- on antiretroviral therapy	0	

## Drug-resistant TB care\*\*, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	0%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	3.1%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	168
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	0
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	88%	87 413
Previously treated cases, excluding relapse, registered in 2021	80%	6 184
HIV-positive TB cases registered in 2021		0
MDR/RR-TB cases started on second-line treatment in 2020	70%	640
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020		0


## TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	8.4% (8.2-8.6)

## Funding for TB

Funding for TB, 2022 (US\$ millions)	0
- % domestic funding	
- % international funding	
National TB budget, 2023 (US\$ millions)	
- Funding source, domestic	
- Funding source, international	
- Unfunded	


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2022



## Cases attributable to five risk factors, 2022 (Number)



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed

---

Generated 2023-12-16 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)